NO20044095L - 5-fenyltiazolderivater og anvendelse som P13 kinaseinhibitorer - Google Patents

5-fenyltiazolderivater og anvendelse som P13 kinaseinhibitorer

Info

Publication number: NO20044095L
Authority: NO; Norway
Prior art keywords: kinase inhibitors; phenylthiazole derivatives; phenylthiazole; derivatives; kinase
Prior art date: 2002-02-28

Application number

NO20044095A

Other languages

English (en)

Other versions

NO329175B1 (no

Inventor

Judy Hayler

Clive Mccarthy

Lan Bruce

Peter Finan

Catherine Leblanc

Lewis Whitehead

Nicola Elaine Press

Graham Charles Bloomfield

Louise Kirman

Mrinalini Sachin Oza

Lena Shukla

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-02-28

Filing date

2004-09-27

Publication date

2004-11-02

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27767104&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20044095(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2002-02-28 Priority claimed from GB0204765A external-priority patent/GB0204765D0/en

2002-12-19 Priority claimed from GB0229626A external-priority patent/GB0229626D0/en

2004-09-27 Application filed by Novartis Ag filed Critical Novartis Ag

2004-11-02 Publication of NO20044095L publication Critical patent/NO20044095L/no

2010-09-06 Publication of NO329175B1 publication Critical patent/NO329175B1/no

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/40—Unsubstituted amino or imino radicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/44—Acylated amino or imino radicals
- C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/44—Acylated amino or imino radicals
- C07D277/48—Acylated amino or imino radicals by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof, e.g. carbonylguanidines
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pulmonology (AREA)
Diabetes (AREA)
Immunology (AREA)
Physical Education & Sports Medicine (AREA)
Dermatology (AREA)
Hematology (AREA)
Orthopedic Medicine & Surgery (AREA)
Neurology (AREA)
Obesity (AREA)
Rheumatology (AREA)
Virology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Urology & Nephrology (AREA)
Otolaryngology (AREA)
Vascular Medicine (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Ophthalmology & Optometry (AREA)
Tropical Medicine & Parasitology (AREA)
Gastroenterology & Hepatology (AREA)
Endocrinology (AREA)
Child & Adolescent Psychology (AREA)
Pain & Pain Management (AREA)
Biomedical Technology (AREA)

NO20044095A 2002-02-28 2004-09-27 5-fenyltiazolderivater, fremgangsmate for fremstilling derav, anvendelse av en slik forbindelse samt farmasoytisk sammensetning inneholdende forbindelsen NO329175B1 (no)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GB0204765A GB0204765D0 (en)	2002-02-28	2002-02-28	Organic compounds
GB0229626A GB0229626D0 (en)	2002-12-19	2002-12-19	Organic compounds
PCT/EP2003/002036 WO2003072557A1 (en)	2002-02-28	2003-02-27	5-phenylthiazole derivatives and use as pi3 kinase inhibitors

Publications (2)

Publication Number	Publication Date
NO20044095L true NO20044095L (no)	2004-11-02
NO329175B1 NO329175B1 (no)	2010-09-06

Family

ID=27767104

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20044095A NO329175B1 (no)	2002-02-28	2004-09-27	5-fenyltiazolderivater, fremgangsmate for fremstilling derav, anvendelse av en slik forbindelse samt farmasoytisk sammensetning inneholdende forbindelsen

Country Status (27)

Country	Link
US (2)	US7687637B2 (no)
EP (1)	EP1480962B1 (no)
JP (2)	JP4408701B2 (no)
KR (1)	KR100688370B1 (no)
CN (1)	CN100548996C (no)
AR (1)	AR038703A1 (no)
AT (1)	ATE521598T1 (no)
AU (1)	AU2003214080A1 (no)
BR (1)	BR0308030A (no)
CA (1)	CA2477601C (no)
CO (1)	CO5611131A2 (no)
CY (2)	CY1112084T1 (no)
DK (2)	DK2311818T3 (no)
EC (2)	ECSP045253A (no)
ES (2)	ES2372597T3 (no)
IL (2)	IL163691A0 (no)
MX (1)	MXPA04008362A (no)
MY (1)	MY156407A (no)
NO (1)	NO329175B1 (no)
NZ (1)	NZ534657A (no)
PE (1)	PE20030968A1 (no)
PL (2)	PL215581B1 (no)
PT (2)	PT1480962E (no)
RU (2)	RU2436780C2 (no)
SI (1)	SI1480962T1 (no)
TW (1)	TWI314928B (no)
WO (1)	WO2003072557A1 (no)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2000018885A1 (en)	1998-09-29	2000-04-06	Gamida Cell Ltd.	Methods of controlling proliferation and differentiation of stem and progenitor cells
IL152904A0 (en)	2002-01-24	2003-06-24	Gamida Cell Ltd	Utilization of retinoid and vitamin d receptor antagonists for expansion of renewable stem cell populations
WO2003062404A1 (en)	2002-01-25	2003-07-31	Gamida-Cell Ltd.	Methods of expanding stem and progenitor cells and expanded cell populations obtained thereby
JP2006517234A (ja)	2003-02-10	2006-07-20	アムジエン・インコーポレーテツド	バニロイド受容体リガンドおよび治療におけるこれらのリガンドの使用
GB0305152D0 (en) *	2003-03-06	2003-04-09	Novartis Ag	Organic compounds
JP4758337B2 (ja) *	2003-03-31	2011-08-24	株式会社アールテック・ウエノ	血管透過性亢進疾患を治療する方法
TW200519106A (en)	2003-05-02	2005-06-16	Novartis Ag	Organic compounds
GB0320197D0 (en)	2003-08-28	2003-10-01	Novartis Ag	Organic compounds
US8802861B2 (en)	2004-01-12	2014-08-12	Merck Serono Sa	Thiazole derivatives and use thereof
SI1809624T1 (sl)	2004-08-28	2014-02-28	Astrazeneca Ab	Derivati pirimidinsulfonamida kot modulatorji receptorja kemokina
RU2403258C2 (ru) *	2004-10-07	2010-11-10	Бёрингер Ингельхайм Интернациональ Гмбх	Тиазолилдигидроиндазолы
UY29149A1 (es) *	2004-10-07	2006-05-31	Boehringer Ingelheim Int	Tiazolil-dihidro-indazoles
SE0402735D0 (sv) *	2004-11-09	2004-11-09	Astrazeneca Ab	Novel compounds
EP1964578A3 (en) *	2005-05-05	2008-11-05	Chroma Therapeutics Limited	Alpha aminoacid ester-drug conjugates hydrolysable by carboxylesterase
EA014350B1 (ru)	2005-05-24	2010-10-29	Мерк Сероно С.А.	Производные тиазола и их применение
EP1888546B1 (en) *	2005-05-24	2015-07-08	Merck Serono SA	Thiazole derivatives and use thereof
US8846393B2 (en)	2005-11-29	2014-09-30	Gamida-Cell Ltd.	Methods of improving stem cell homing and engraftment
EP1968597A4 (en) *	2005-12-01	2012-01-11	Scripps Research Inst	COMPOSITIONS AND METHODS FOR INDUCTION OF NEURON DIFFERENTIATION
GB0525671D0 (en) *	2005-12-16	2006-01-25	Novartis Ag	Organic compounds
EP1981884B1 (en) *	2006-01-18	2012-06-13	Amgen, Inc	Thiazole compounds as protein kinase b (pkb) inhibitors
EP1991528A2 (en) *	2006-01-18	2008-11-19	Siena Biotech S.p.A.	Modulators of alpha7 nicotinic acetylcholine receptors and therapeutic uses thereof
US20090029997A1 (en) *	2006-01-23	2009-01-29	Laboratoires Serono Sa	Thiazole Derivatives and Use Thereof
US7517995B2 (en)	2006-04-06	2009-04-14	Boehringer Ingelheim International Gmbh	Thiazolyl-dihydro-cyclopentapyrazole
US20070238746A1 (en) *	2006-04-06	2007-10-11	Trixi Brandl	Thiazolyl-dihydro-chinazoline
US7691868B2 (en)	2006-04-06	2010-04-06	Boehringer Ingelheim International Gmbh	Thiazolyl-dihydro-quinazoline
WO2007129044A1 (en) *	2006-05-03	2007-11-15	Astrazeneca Ab	Thiazole derivatives and their use as anti-tumour agents
GB0608854D0 (en) *	2006-05-04	2006-06-14	Chroma Therapeutics Ltd	P13 kinase inhibitors
GB0608823D0 (en) *	2006-05-04	2006-06-14	Chroma Therapeutics Ltd	Inhibitors of P13 kinase
GB0610243D0 (en) *	2006-05-23	2006-07-05	Novartis Ag	Organic compounds
GB0612630D0 (en) *	2006-06-26	2006-08-02	Novartis Ag	Organic compounds
RU2435763C2 (ru) *	2006-06-27	2011-12-10	Дзе Проктер Энд Гэмбл Компани	Ингибиторы тирозинфосфатазы белка человека и способы применения
US7589212B2 (en) *	2006-06-27	2009-09-15	Procter & Gamble Company	Human protein tyrosine phosphatase inhibitors and methods of use
DK1887359T3 (da) *	2006-08-03	2009-03-02	Cellzome Ag	Fremgangsmåde til identifikation af PI3K-interagerende molekyler og til rensning af PI3K
EP2061787A2 (en)	2006-09-01	2009-05-27	Vertex Pharmaceuticals Incorporated	5-(2-furyl)-1,3-thiazole derivatives useful as inhibitors of phosphatidylinositol 3-kinase
CA2670736A1 (en) *	2006-11-29	2008-06-05	Abbott Laboratories	Inhibitors of diacylglycerol o-acyltransferase type 1 enzyme
PE20090717A1 (es) *	2007-05-18	2009-07-18	Smithkline Beecham Corp	Derivados de quinolina como inhibidores de la pi3 quinasa
EP2572712A3 (en)	2007-06-01	2013-11-20	The Trustees Of Princeton University	Treatment of viral infections by modulation of host cell metabolic pathways
CA2693473A1 (en) *	2007-07-17	2009-01-22	Amgen Inc.	Thiadiazole modulators of pkb
AU2008276521B2 (en)	2007-07-17	2011-11-03	Amgen Inc.	Heterocyclic modulators of PKB
EA201000947A1 (ru) *	2007-12-20	2011-02-28	Новартис Аг	Производные тиазола, применимые в качестве ингибиторов киназы pi3
CA2713276A1 (en)	2008-02-04	2009-08-13	Cellzome Ag	Selectivity profiling of pi3k interacting molecules against multiple targets
UA104147C2 (uk)	2008-09-10	2014-01-10	Новартис Аг	Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
CN101684106B (zh) *	2008-09-22	2013-06-12	北京摩力克科技有限公司	噻唑鎓盐类化合物及其治疗蛋白老化相关疾病的用途
SG173884A1 (en) *	2009-02-27	2011-10-28	Teijin Pharma Ltd	Process for producing phenyl-substituted heterocyclic derivative through coupling using transition metal catalyst
TW201103943A (en) *	2009-04-27	2011-02-01	Shionogi & Co	Urea derivative having pi3k inhibitory activity
US8293753B2 (en)	2009-07-02	2012-10-23	Novartis Ag	Substituted 2-carboxamide cycloamino ureas
CA2766853A1 (en)	2009-07-02	2011-01-06	Novartis Ag	2-carboxamide cycloamino ureas useful as pi3k inhibitors
GB0913345D0 (en)	2009-07-31	2009-09-16	Astrazeneca Ab	New combination 802
JPWO2011048936A1 (ja)	2009-10-19	2013-03-07	大正製薬株式会社	アミノチアゾール誘導体
WO2011061527A1 (en)	2009-11-17	2011-05-26	Astrazeneca Ab	Combinations comprising a glucocorticoid receptor modulator for the treatment of respiratory diseases
EP2992878A1 (en)	2010-02-03	2016-03-09	Signal Pharmaceuticals, LLC	Identification of lkb1 mutation as a predictive biomarker for sensitivity to tor kinase inhibitors
WO2012071480A2 (en) *	2010-11-24	2012-05-31	Lithera, Inc.	Lipophilic glucocorticosteroid monotherapeutic formulations and methods for the cosmetic treatment of adiposity and contour bulging
GB201021992D0 (en)	2010-12-23	2011-02-02	Astrazeneca Ab	Compound
GB201021979D0 (en)	2010-12-23	2011-02-02	Astrazeneca Ab	New compound
AU2012290056B2 (en)	2011-08-03	2015-03-19	Signal Pharmaceuticals, Llc	Identification of gene expression profile as a predictive biomarker for LKB1 status
US9926309B2 (en)	2011-10-05	2018-03-27	The Board Of Trustees Of The Leland Stanford Junior University	Pi-kinase inhibitors with anti-infective activity
EP2763532B1 (en) *	2011-10-05	2018-09-19	The Board of Trustees of the Leland Stanford Junior University	Pi-kinase inhibitors with broad spectrum anti-infective activity
WO2013121426A1 (en)	2012-02-13	2013-08-22	Gamida-Cell Ltd.	Culturing of mesenchymal stem cells
US9175266B2 (en)	2012-07-23	2015-11-03	Gamida Cell Ltd.	Enhancement of natural killer (NK) cell proliferation and activity
US9567569B2 (en)	2012-07-23	2017-02-14	Gamida Cell Ltd.	Methods of culturing and expanding mesenchymal stem cells
AU2013203714B2 (en)	2012-10-18	2015-12-03	Signal Pharmaceuticals, Llc	Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
CA2909579A1 (en)	2013-04-17	2014-10-23	Signal Pharmaceuticals, Llc	Combination therapy comprising a tor kinase inhibitor and n-(3-(5-fluoro-2-(4-(2-methoxyethoxy)phenylamino)pyrimidin-4-ylamino)phenyl)acrylamide for treating cancer
KR102459285B1 (ko)	2013-04-17	2022-10-27	시그날 파마소티칼 엘엘씨	1-에틸-7-(2-메틸-6-(1H-1,2,4-트리아졸-3-일)피리딘-3-일)-3,4-디하이드로피라지노[2,3-b]피라진-2(1H)-온에 관한 약학 제제, 제조방법, 고체 형태 및 사용 방법
KR102221029B1 (ko)	2013-04-17	2021-02-26	시그날 파마소티칼 엘엘씨	디하이드로피라지노-피라진을 사용한 암의 치료
TWI654979B (zh)	2013-04-17	2019-04-01	美商標誌製藥公司	使用ｔｏｒ激酶抑制劑組合療法以治療癌症之方法
JP6382945B2 (ja)	2013-04-17	2018-08-29	シグナルファーマシューティカルズ，エルエルシー	ジヒドロピラジノ−ピラジンによる癌治療
WO2014172432A1 (en)	2013-04-17	2014-10-23	Signal Pharmaceuticals, Llc	Combination therapy comprising a tor kinase inhibitor and a cytidine analog for treating cancer
WO2014172431A1 (en)	2013-04-17	2014-10-23	Signal Pharmaceuticals, Llc	Combination therapy comprising a dihydropyrazino-pyrazine compound and an androgen receptor antagonist for treating prostate cancer
CN113831345A (zh)	2013-05-29	2021-12-24	西格诺药品有限公司	二氢吡嗪并吡嗪化合物的药物组合物、其固体形式和它们的用途
CN104418858B (zh)	2013-08-30	2018-12-11	浙江医药股份有限公司新昌制药厂	2,6-二含氮取代的嘌呤衍生物及其制备方法和其药物组合物与应用
DE102013226711A1 (de) *	2013-12-19	2015-06-25	Beiersdorf Ag	Verwendung von Alkylamidothiazolen in kosmetischen oder dermatologischen Zubereitungen zur Prophylaxe vor und Behandlung von sensibler Haut
NZ714742A (en)	2014-04-16	2017-04-28	Signal Pharm Llc	Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
EP3131551A4 (en)	2014-04-16	2017-09-20	Signal Pharmaceuticals, LLC	SOLID FORMS COMPRISING 1-ETHYL-7-(2-METHYL-6-(1H-1,2,4-TRIAZOL-3-YL) PYRIDIN-3-YL)-3,4-DIHYDROPYRAZINO(2,3-b)PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF
WO2015162584A1 (en)	2014-04-24	2015-10-29	Novartis Ag	Crystalline forms of the sulfate salt of n-[5-(3-imidazol-1-yl-4-methanesulfonyl-phenyl)-4-methyl-thiazol-2-yl]-acetamide
WO2016065583A1 (en) *	2014-10-30	2016-05-06	Merck Sharp & Dohme Corp.	Oxazole orexin receptor antagonists
MX2018002331A (es) *	2015-09-04	2018-07-06	Dow Agrosciences Llc	Moleculas que tienen utilidad plaguicida, e intermediarios, composiciones y procesos, relacionados con ellas.
US9661853B2 (en) *	2015-09-04	2017-05-30	Dow Agrosciences Llc	Molecules having pesticidal utility, and intermediates, compositions, and processes, related thereto
AU2016318336B2 (en) *	2015-09-10	2018-09-27	Corteva Agriscience Llc	Molecules having pesticidal utility, and intermediates, compositions, and processes, related thereto
PT3395801T (pt)	2015-12-16	2021-05-24	Nippon Soda Co	Composto de arilazol e agente de controlo de pragas
EP3411391B1 (en)	2016-02-01	2021-11-10	The Governing Council of the University of Toronto	Ubiquitin variants and uses thereof as 53bp1 inhibitors
US11091472B2 (en)	2016-02-26	2021-08-17	The Regents Of The University Of California	PI-kinase inhibitors with anti-infective activity
SG11201912403SA (en)	2017-06-22	2020-01-30	Celgene Corp	Treatment of hepatocellular carcinoma characterized by hepatitis b virus infection
WO2019101871A1 (en) *	2017-11-23	2019-05-31	Inserm (Institut National De La Sante Et De La Recherche Medicale)	A new marker for predicting the sensitivity to pi3k inhibitors
JP7701051B2 (ja) *	2019-03-21	2025-07-01	ザボードオブトラスティスオブザリーランドスタンフォードジュニアユニヴァーシティー	Ｐｉ４－キナーゼ阻害剤及びその使用方法
PE20220346A1 (es) *	2019-08-28	2022-03-14	Novartis Ag	Derivados de 1,3-fenil heteroarilo sustituidos y su uso en el tratamiento de enfermedades
CN115028596B (zh) *	2021-03-03	2024-06-07	帕潘纳(北京)科技有限公司	制备苯唑草酮中间体的方法
EP4638477A1 (en)	2022-12-19	2025-10-29	Kamau Therapeutics, Inc.	Improved peptide inhibitors of p53 binding protein 53bp1

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB951885A (en)	1961-05-13	1964-03-11	Sankyo Co	A new process for the preparation of thiazole compounds
OA01933A (fr)	1965-04-06	1970-02-04	Pechiney Saint Gobain	Dérivés du thiazole.
US3749775A (en) *	1969-07-07	1973-07-31	Stauffer Chemical Co	Insecticidal 2-aminothiazole phosphates and phosphonates
FR2429210A1 (fr)	1978-06-19	1980-01-18	Fabre Sa Pierre	Derives de phenyl-4 thiazolyl-2 oxamates utiles dans le traitement de l'asthme
JPS57136579A (en)	1981-01-21	1982-08-23	Mitsui Toatsu Chem Inc	Thiazolylurea derivative, its preparation, and pharmaceutical composition containing the same
US4511574A (en)	1981-01-08	1985-04-16	Mitsui Toatsu Kagaku Kabushiki Kaisha	N-(4-Phenyl-2-thiazolyl)carbamate derivatives
DE3413755A1 (de)	1984-04-12	1985-10-24	Basf Ag, 6700 Ludwigshafen	Thiazolylharnstoffe, verfahren zu ihrer herstellung und ihre verwendung zur bekaempfung unerwuenschten pflanzenwuchses
JPH0725754B2 (ja)	1986-01-30	1995-03-22	富山化学工業株式会社	新規なチアゾール化合物またはその塩
EP0321115B1 (en)	1987-12-14	1991-08-14	Sawai Pharmaceutical Co., Ltd.	Carboxamide derivatives having tetrazole and thiazole rings and their use
US4891375A (en)	1988-01-13	1990-01-02	Pfizer Inc.	Arylpiperazinyl-alkylene-phenyl-heterocyclic compounds
DK1130017T3 (da)	1990-11-30	2005-10-10	Otsuka Pharma Co Ltd	Azolderivater og deres anvendelse som superoxidradikalinhibitorer
DE4401911A1 (de)	1994-01-24	1995-08-03	Basf Ag	Verwendung von Aryl- oder Heteroarylazoanilinen in der nichtlinearen Optik
EP0772606A1 (en)	1994-07-27	1997-05-14	G.D. SEARLE & CO.	Substituted thiazoles for the treatment of inflammation
US5856347A (en) *	1994-11-29	1999-01-05	Hisamitsu Pharmaceutical Co., Inc.	Antibacterial preparation or bactericide comprising 2-aminothiazole derivative and/or salt thereof
GB9625843D0 (en) *	1996-12-12	1997-01-29	Merck & Co Inc	Phenyl spiroethercycloalkyl tachykinn receptor antagonists
DK1047418T3 (da)	1997-12-22	2005-11-21	Bayer Pharmaceuticals Corp	Inhibering af raf-kinase ved hjælp af substituerede heterocykliske urinstoffer
EP0928790B1 (en)	1998-01-02	2003-03-05	F. Hoffmann-La Roche Ag	Thiazole derivatives
US6100282A (en) *	1998-01-02	2000-08-08	Hoffman-La Roche Inc.	Thiazole derivatives
US6043254A (en)	1998-04-03	2000-03-28	Boehringer Ingelheim Pharma Kg	Indolinones having kinase-inhibiting activity
GB9823873D0 (en) *	1998-10-30	1998-12-30	Pharmacia & Upjohn Spa	2-ureido-thiazole derivatives,process for their preparation,and their use as antitumour agents
DE60128655T2 (de) *	2000-01-24	2008-02-07	Astrazeneca Ab	Durch einen morpholinrest substituierte therapeutische verbindungen
US6518277B1 (en)	2000-04-25	2003-02-11	Icos Corporation	Inhibitors of human phosphatidylinositol 3-kinase delta
CZ2003237A3 (cs) *	2000-07-26	2003-06-18	Bristol-Myers Squibb Company	N-(5-{[(5-Alkyl-2-oxazolyl)methyl]thio}-2-thiazolyl) karboxamidy jako inhibitory cyklin-dependentních kináz
CN100370975C (zh)	2000-12-18	2008-02-27	株式会社医药分子设计研究所	炎症性细胞因子产生游离抑制剂
AR039059A1 (es) *	2001-08-06	2005-02-09	Sanofi Aventis	Compuesto derivado de acilaminotiazol, su utilizacion, procedimientos para prepararlo, composicion farmaceutica que lo comprende, y compuestos intermediarios
US20040242637A1 (en) *	2001-08-17	2004-12-02	Hartman George D	Tyrosine kinase inhibitors
US6812653B2 (en) *	2002-07-26	2004-11-02	Richard S. Bellivean	Method and apparatus for controlling images with image projection lighting devices
GB0525671D0 (en) *	2005-12-16	2006-01-25	Novartis Ag	Organic compounds

2003
- 2003-02-26 AR ARP030100626A patent/AR038703A1/es active IP Right Grant
- 2003-02-26 MY MYPI20030662A patent/MY156407A/en unknown
- 2003-02-26 TW TW092104036A patent/TWI314928B/zh not_active IP Right Cessation
- 2003-02-26 PE PE2003000188A patent/PE20030968A1/es not_active Application Discontinuation
- 2003-02-27 PL PL370575A patent/PL215581B1/pl unknown
- 2003-02-27 ES ES03709730T patent/ES2372597T3/es not_active Expired - Lifetime
- 2003-02-27 WO PCT/EP2003/002036 patent/WO2003072557A1/en not_active Ceased
- 2003-02-27 AU AU2003214080A patent/AU2003214080A1/en not_active Abandoned
- 2003-02-27 NZ NZ534657A patent/NZ534657A/en not_active IP Right Cessation
- 2003-02-27 BR BR0308030-7A patent/BR0308030A/pt not_active IP Right Cessation
- 2003-02-27 EP EP03709730A patent/EP1480962B1/en not_active Expired - Lifetime
- 2003-02-27 IL IL16369103A patent/IL163691A0/xx unknown
- 2003-02-27 AT AT03709730T patent/ATE521598T1/de active
- 2003-02-27 US US10/504,259 patent/US7687637B2/en not_active Expired - Fee Related
- 2003-02-27 MX MXPA04008362A patent/MXPA04008362A/es active IP Right Grant
- 2003-02-27 CN CNB038047969A patent/CN100548996C/zh not_active Expired - Fee Related
- 2003-02-27 RU RU2009132712/04A patent/RU2436780C2/ru not_active IP Right Cessation
- 2003-02-27 DK DK10174528.9T patent/DK2311818T3/da active
- 2003-02-27 JP JP2003571263A patent/JP4408701B2/ja not_active Expired - Fee Related
- 2003-02-27 RU RU2004129279/04A patent/RU2378263C2/ru not_active IP Right Cessation
- 2003-02-27 PL PL403456A patent/PL219449B1/pl unknown
- 2003-02-27 ES ES10174528T patent/ES2405816T3/es not_active Expired - Lifetime
- 2003-02-27 PT PT03709730T patent/PT1480962E/pt unknown
- 2003-02-27 CA CA2477601A patent/CA2477601C/en not_active Expired - Fee Related
- 2003-02-27 KR KR1020047013419A patent/KR100688370B1/ko not_active Expired - Fee Related
- 2003-02-27 DK DK03709730.0T patent/DK1480962T3/da active
- 2003-02-27 PT PT101745289T patent/PT2311818E/pt unknown
- 2003-02-27 SI SI200332074T patent/SI1480962T1/sl unknown
2004
- 2004-08-23 IL IL163691A patent/IL163691A/en not_active IP Right Cessation
- 2004-08-28 EC EC2004005253A patent/ECSP045253A/es unknown
- 2004-09-15 CO CO04091790A patent/CO5611131A2/es active IP Right Grant
- 2004-09-27 NO NO20044095A patent/NO329175B1/no not_active IP Right Cessation
2009
- 2009-08-12 JP JP2009187248A patent/JP2009298799A/ja active Pending
- 2009-12-17 US US12/640,479 patent/US8129541B2/en not_active Expired - Fee Related
2010
- 2010-08-30 EC EC2010005253A patent/ECSP105253A/es unknown
2011
- 2011-11-24 CY CY20111101144T patent/CY1112084T1/el unknown
2013
- 2013-04-16 CY CY20131100312T patent/CY1114083T1/el unknown

Also Published As

Publication number	Publication date
JP2005522458A (ja)	2005-07-28
ATE521598T1 (de)	2011-09-15
AR038703A1 (es)	2005-01-26
DK2311818T3 (da)	2013-05-06
CY1114083T1 (el)	2016-07-27
TW200303750A (en)	2003-09-16
AU2003214080A1 (en)	2003-09-09
ECSP105253A (es)	2010-09-30
US7687637B2 (en)	2010-03-30
ES2405816T3 (es)	2013-06-03
RU2009132712A (ru)	2011-03-10
ECSP045253A (es)	2004-09-28
EP1480962B1 (en)	2011-08-24
TWI314928B (en)	2009-09-21
CA2477601A1 (en)	2003-09-04
JP2009298799A (ja)	2009-12-24
RU2378263C2 (ru)	2010-01-10
CO5611131A2 (es)	2006-02-28
CN100548996C (zh)	2009-10-14
NZ534657A (en)	2007-05-31
CA2477601C (en)	2011-05-24
CN1639139A (zh)	2005-07-13
IL163691A0 (en)	2005-12-18
PE20030968A1 (es)	2004-01-12
KR20040091674A (ko)	2004-10-28
HK1071363A1 (en)	2005-07-15
PL370575A1 (en)	2005-05-30
PL403456A1 (pl)	2013-05-27
CY1112084T1 (el)	2015-11-04
PT1480962E (pt)	2011-12-15
JP4408701B2 (ja)	2010-02-03
PL219449B1 (pl)	2015-04-30
NO329175B1 (no)	2010-09-06
US20100093690A1 (en)	2010-04-15
BR0308030A (pt)	2004-12-28
MXPA04008362A (es)	2004-11-26
ES2372597T3 (es)	2012-01-24
US8129541B2 (en)	2012-03-06
KR100688370B1 (ko)	2007-03-02
MY156407A (en)	2016-02-26
US20050119320A1 (en)	2005-06-02
SI1480962T1 (sl)	2011-12-30
PT2311818E (pt)	2013-05-15
PL215581B1 (pl)	2013-12-31
DK1480962T3 (da)	2011-12-05
WO2003072557A1 (en)	2003-09-04
RU2436780C2 (ru)	2011-12-20
IL163691A (en)	2010-11-30
EP1480962A1 (en)	2004-12-01
RU2004129279A (ru)	2005-06-27

Publication	Publication Date	Title
NO20044095L (no)	2004-11-02	5-fenyltiazolderivater og anvendelse som P13 kinaseinhibitorer
NO20053356D0 (no)	2005-07-11	Aminindazolderivater og anvendelse derav som kinaseinhibitorer.
DK2305250T3 (da)	2014-04-22	Benzimidazolderivater og anvendelse heraf som proteinkinaseinhibitorer
DK1499311T3 (da)	2010-03-08	Substituerede benzaboler og anvendelse deraf som RAF-kinaseinhibitorer
IS6934A (is)	2003-08-29	Nýjar spírótrísýklískar afleiður og notkun þeirrasem fosfódíesterasa-7-hindrar
DK1527050T3 (da)	2010-07-19	Quinolin-derivater og deres anvendelse som mycobakterielle inhibitorer
DK1480955T3 (da)	2007-10-29	O-cyclopropyl-carboxanilider og deres anvendelse som fungicider
DK1501815T3 (da)	2007-04-02	Substituerede phenylacetamider og anvendelse deraf som glucokinaseaktivatorer
DK1558615T3 (da)	2007-12-03	Purin-forbindelser og deres anvendelse som cannabinoid receptor ligander
NO20026010D0 (no)	2002-12-13	Substituerte quinazolinderivater og deres anvendelse som inhibitorer
DK1465615T3 (da)	2012-11-12	Tricykliske bisenonderivater og fremgangsmåder til anvendelse heraf
DK1492785T3 (da)	2009-03-02	2-hydroxy-3-heteroarylindol-derivater som GSK3-inhibitorer
DK1578755T3 (da)	2007-11-12	Phosphonooxyguinalinderivater og deres farmaceutiske anvendelse
DK1592686T3 (da)	2009-10-19	Gyrase-inhibitorer og anvendelser deraf
IS7646A (is)	2005-01-12	Azaindól kínasatálmar
DK1401806T3 (da)	2006-11-27	Benzoylsulfonamider og sulfonylbenzamidiner til anvendelse som antitumormidler
NO20052524D0 (no)	2005-05-26	Aminerte isofiavonoidderivater og anvendelse derav
DK1133477T3 (da)	2004-06-21	Substituerede benzimidazoler og deres anvendelse som parpinhibitorer
DK1564210T3 (da)	2009-11-16	4-Oxoquinolinforbindelser og anvendelse deraf som HIV-integraseinhibitorer
NO20034324L (no)	2003-09-26	Bipiperidinylderivater og deres anvendelse som kjemokin reseptorinhibitor
NO20042719L (no)	2004-06-28	Substituerte 2-amino-cykloalkankarboksamider og deres anvendelse som protease-inhibitorer
NO20050665L (no)	2005-04-18	Pyrrolidonderivater som MAOE inhibitoere
NO20043580D0 (no)	2004-08-27	Quinazolinonderivater og deres bruk som CB agonister
NO20044665L (no)	2004-12-03	Renzoksazin-derivater som 5-HT6-modulatorer og anvendelser derav
DK1387838T3 (da)	2006-08-14	Cyanoanthranylamid-derivater og deres anvendelse som lægemidler

Legal Events

Date	Code	Title	Description
2016-09-26	MM1K	Lapsed by not paying the annual fees